THE CHROMOSOME | Clinical Content Series
Oestrogen Dominance
Back to Case Studies ArchiveCase Study
She was 37 years old and described her body as having changed completely over the previous four years in ways she could neither explain nor control. The weight had arrived differently to anything she had experienced before, settling predominantly around her hips, thighs, and lower abdomen in a pattern that felt hormonal rather than dietary, though she could not have articulated why she felt that. Her breasts had become tender and swollen in the week before each period. Her periods themselves had become heavier, more painful, and increasingly irregular. She was bloated almost continuously. She was emotional in ways that frightened her, crying without clear reason, experiencing anxiety that arrived without warning and departed without explanation, feeling a rage in the days before her period that she described as belonging to someone else entirely.
She had been told this was stress. She had been told it was her age. She had been prescribed the contraceptive pill by one physician and an antidepressant by another. Neither had been explained to her in terms of what was actually happening in her biology. Neither had worked in any meaningful sense.
She had also gained 18 kilograms across those four years. The weight and the symptoms had arrived together, which was not a coincidence, because they shared the same hormonal origin.
When I evaluated her full hormonal profile the picture was entirely consistent with what I identify as oestrogen dominance, a state in which oestrogen is elevated, or more precisely, in which oestrogen is excessive relative to progesterone, creating a hormonal imbalance that drives a specific and recognisable constellation of symptoms, metabolic changes, and weight gain patterns that Pakistani medicine almost never identifies correctly because progesterone is almost never measured alongside oestrogen in standard hormonal panels.
Her total oestrogen was elevated. Her progesterone was severely low, producing an oestrogen to progesterone ratio so imbalanced that the clinical picture it generated was one of the most florid I had seen at her age. Her testosterone was low. Her SHBG was elevated, trapping the limited testosterone available and reducing its biological activity further. Her cortisol pattern was dysregulated, which was both a cause and a consequence of the oestrogen dominance, because cortisol and progesterone compete for the same receptor pathways, and chronic cortisol elevation systematically depletes progesterone. Her liver enzymes were mildly elevated, reflecting the hepatic burden of oestrogen clearance in a patient whose liver was already managing a significant metabolic load from visceral fat accumulation.
This was not stress. This was not her age. This was a precisely identifiable hormonal imbalance with a biological origin, a metabolic consequence, and a clinical solution, none of which had been offered to her before she sat across from me.
The FTO gene's influence on oestrogen metabolism in Pakistani women creates a predisposition to oestrogen dominance that is amplified by visceral fat accumulation, because visceral fat contains the enzyme aromatase, which converts androgens to oestrogen peripherally, adding to ovarian oestrogen production and creating an oestrogen excess that the liver must then clear. In Pakistani women, whose liver is frequently already burdened by the metabolic consequences of insulin resistance and fatty infiltration, oestrogen clearance is impaired, allowing oestrogen to accumulate further. The FTO associated predisposition to visceral fat accumulation at lower body weight thresholds in Pakistani women means this oestrogen amplification begins earlier and progresses faster than Western clinical models anticipate.
We did not prescribe the contraceptive pill, which adds synthetic oestrogen to an already oestrogen dominant system and deepens the imbalance it purports to treat. We addressed the progesterone deficiency directly. We reduced the visceral fat driving peripheral oestrogen production through aromatase activity. We supported hepatic oestrogen clearance through targeted nutritional intervention. We recalibrated the cortisol pattern that had been depleting her progesterone. We addressed the insulin resistance that had been suppressing SHBG and amplifying the biological activity of her excess oestrogen.
Twelve months later she had lost 16 kilograms. Her periods had normalised in duration, flow, and pain. Her premenstrual symptoms had resolved almost completely. Her mood had stabilised in a way she described as finally feeling like herself again.
She had not been stressed. She had been hormonally overwhelmed, by a precisely identifiable imbalance that had been present and worsening for four years while she was being managed with medications that had never been appropriate for her condition.
FAQs
Oestrogen dominance is a hormonal state in which oestrogen is excessive relative to progesterone, either because oestrogen is elevated, progesterone is depleted, or both simultaneously. It produces a recognisable constellation of symptoms including weight gain around the hips and thighs, breast tenderness, heavy and painful periods, bloating, mood instability, anxiety, and premenstrual rage. It is almost universally missed in Pakistani clinical practice because standard hormonal panels measure oestrogen and testosterone without measuring progesterone, making the imbalance between oestrogen and progesterone invisible to the physician ordering the test. Dr. Zaar measures the full oestrogen progesterone ratio as a standard component of every female hormonal assessment, because the ratio matters more than either hormone measured in isolation.
Oestrogen dominance drives weight gain through a pattern that is distinctively different from cortisol or insulin driven obesity, accumulating predominantly in the hips, thighs, lower abdomen, and breast tissue rather than the central visceral pattern of insulin driven weight gain. Excess oestrogen promotes fat cell proliferation in these oestrogen receptor rich areas, promotes water and sodium retention producing the bloating and puffiness characteristic of oestrogen excess, suppresses thyroid function by increasing thyroid binding globulin and reducing free thyroid hormone availability, and drives insulin resistance independently, creating a compound metabolic burden. In Pakistani women, the FTO associated predisposition to visceral fat accumulation amplifies oestrogen production through peripheral aromatase activity, adding an external oestrogen source to an already imbalanced hormonal picture.
The FTO gene at Chromosome 16q12.2 promotes visceral fat accumulation at lower body weight thresholds in Pakistani women than in Western populations, and visceral fat is a primary site of peripheral oestrogen production through aromatase enzyme activity. As visceral fat accumulates, aromatase activity increases proportionally, converting androgens to oestrogen and adding to ovarian oestrogen production in ways that overwhelm the liver's clearance capacity. The FTO associated metabolic profile also promotes the insulin resistance that suppresses SHBG production, increasing the biological activity of circulating oestrogen by reducing the protein that binds and inactivates it. Dr. Zaar identifies this FTO amplified oestrogen production pathway as a specific and clinically important contributor to oestrogen dominance in Pakistani women presenting with visceral obesity.
The contraceptive pill introduces synthetic oestrogen, or synthetic progestins that do not replicate the biological activity of natural progesterone, into a hormonal system that is already oestrogen dominant. Synthetic oestrogen adds to the existing oestrogen excess. Synthetic progestins, while they suppress ovulation, do not provide the progesterone receptor activity that natural progesterone delivers, meaning the progesterone deficiency that underlies the oestrogen dominance remains unaddressed. The pill may regulate the menstrual cycle mechanically while the hormonal imbalance it is prescribed to treat continues to worsen beneath the pharmaceutical surface. Pakistani women prescribed the pill for oestrogen dominance symptoms are being offered symptomatic management of a condition whose biological origin the medication does not address and in many cases actively deepens.
Cortisol and progesterone are synthesised from the same precursor, pregnenolone, and compete for the same biosynthetic pathway. When chronic stress drives sustained cortisol production, the body prioritises cortisol synthesis at the expense of progesterone, a phenomenon sometimes described as the pregnenolone steal. In Pakistani women under chronic stress, which is the majority of Pakistani women managing domestic, professional, and social obligations simultaneously, this cortisol driven progesterone depletion is a primary driver of oestrogen dominance. Treating the stress and cortisol dysregulation without addressing the progesterone deficiency it has produced is incomplete. THE CHROMOSOME protocol treats both simultaneously, because they share the same biological origin.
Excess oestrogen stimulates the liver to produce increased quantities of thyroid binding globulin, the protein that transports thyroid hormone in the bloodstream. When thyroid binding globulin is elevated, a greater proportion of circulating thyroid hormone is bound and therefore biologically inactive, reducing the free thyroid hormone available to tissues regardless of total thyroid hormone levels. Pakistani women with oestrogen dominance frequently present with symptoms of hypothyroidism, fatigue, weight gain, cold intolerance, cognitive slowing, while their standard TSH and total thyroid hormone measurements appear normal, because the free fraction that actually enters cells and drives metabolism is suppressed by oestrogen driven protein binding. This thyroid oestrogen interaction is almost never evaluated in Pakistani clinical practice.
The mood consequences of oestrogen dominance in Pakistani women are among its most debilitating manifestations and among the most consistently misattributed to psychological causes. Excess oestrogen relative to progesterone disrupts GABA receptor sensitivity, reducing the calming neurotransmitter activity that progesterone normally provides and producing anxiety, emotional volatility, sleep disruption, and the premenstrual dysphoria that many Pakistani women experience as a personality change in the days before their period. Low progesterone also reduces serotonin synthesis and activity, contributing to the low mood and emotional fragility that leads Pakistani physicians to prescribe antidepressants for what is fundamentally a hormonal imbalance. THE CHROMOSOME protocol restores the oestrogen progesterone balance, which resolves the mood symptoms at their hormonal origin rather than managing them pharmaceutically.
Chronically elevated oestrogen is a well established driver of breast tissue proliferation, stimulating oestrogen receptor positive breast cells to divide and multiply at an accelerated rate. In Pakistani women with oestrogen dominance, this sustained oestrogenic stimulation of breast tissue produces the cyclical breast tenderness and swelling that characterises the condition, and over the long term creates the proliferative breast environment associated with increased fibrocystic breast disease and elevated breast cancer risk. Pakistani women with oestrogen dominance, visceral obesity, and impaired hepatic oestrogen clearance carry a breast health risk that extends beyond the metabolic and reproductive consequences of the hormonal imbalance. THE CHROMOSOME protocol addresses oestrogen dominance as a breast health intervention as much as a metabolic and reproductive one, because the long term consequences of untreated oestrogen excess in Pakistani women reach well beyond the symptoms that bring them to the clinic.